6323:TSERorze Corporation Analysis
Data as of 2026-05-18 - not real-time
¥3,672.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
The 20‑day SMA sits comfortably above the 50‑day and 200‑day averages, signaling a broad‑based bullish framework. However, the price is trading below the 20‑day SMA, indicating short‑term weakness. The RSI hovers around the midpoint, suggesting no immediate overbought pressure. MACD remains in bearish territory with a negative histogram, reinforcing the near‑term downside bias. Volume has been on a decreasing trend, which may limit upside momentum. A high 30‑day volatility reading and a beta above one point three underscore heightened price swings. The current market price sits well above the DCF‑derived fair value, pointing to an overvalued valuation.
Fundamentally, the company delivers solid gross and operating margins despite a modest revenue contraction. Cash on hand far exceeds debt, and the debt‑to‑equity ratio remains low, providing a strong balance‑sheet cushion. Return on equity is in the double‑digit range, indicating efficient capital deployment. The dividend payout is modest, supporting dividend sustainability. Analyst consensus leans toward a strong‑buy, and the market sentiment index reflects “Extreme Greed,” suggesting optimism may be pricing in future growth.
Fundamentally, the company delivers solid gross and operating margins despite a modest revenue contraction. Cash on hand far exceeds debt, and the debt‑to‑equity ratio remains low, providing a strong balance‑sheet cushion. Return on equity is in the double‑digit range, indicating efficient capital deployment. The dividend payout is modest, supporting dividend sustainability. Analyst consensus leans toward a strong‑buy, and the market sentiment index reflects “Extreme Greed,” suggesting optimism may be pricing in future growth.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price below short‑term SMA
- bearish MACD histogram
- declining volume
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- bullish SMA alignment across timeframes
- strong cash position
- low payout ratio
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- valuation above DCF fair value
- sustained dividend
- moderate sector cyclicality
Key Metrics & Analysis
Financial Health
Revenue Growth-2.40%
Profit Margin14.79%
P/E Ratio33.6
ROE13.02%
ROA10.10%
Debt/Equity17.00
P/B Ratio4.9
Op. Cash Flow¥31.2B
Free Cash Flow¥22.1B
Industry P/E38.2
Technical Analysis
TrendBullish
RSI50.4
Support¥3,491.00
Resistance¥4,210.00
MA 20¥3,790.45
MA 50¥3,293.77
MA 200¥2,587.42
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61
Valuation
Fair Value¥1,941.87
Target Price¥4,550.00
Upside/Downside23.91%
GradeOvervalued
TypeGrowth
Dividend Yield0.54%
Risk Assessment
Beta1.34
Volatility85.77%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.